SS Innovations International (NASDAQ: SSII) has appointed veteran medical technology finance executive Sarah M. Romano as chief financial officer, effective August 3, 2026, the company announced July 20. Romano brings more than two decades of experience in public-company finance, capital markets, and medical technology, having raised over $100 million during her career. The appointment comes as the developer of the SSi Mantra surgical robotic system continues pursuing U.S. Food and Drug Administration clearance while expanding its global footprint.
Romano joins SS Innovations from Vicarious Surgical, another robotic surgery developer, where she served as CFO and led financial and operational initiatives to reduce cash burn and strengthen the balance sheet. Her expertise is expected to be instrumental as SS Innovations prepares for FDA review, detailed in its regulatory filings, and scales its commercial operations internationally.
The company recently graduated the inaugural class of its SS International Centre for Robotics Surgery (SSICRS) cardiac robotic surgery training program, which welcomed 33 healthcare professionals from seven countries. This milestone underscores SS Innovations' dual focus on technology deployment and surgeon education, a strategy designed to build a skilled user base for the SSi Mantra platform.
With Romano at the financial helm, SS Innovations aims to navigate the capital-intensive path to FDA clearance and broader adoption. Her track record in capital markets is expected to help the company secure funding for clinical trials and manufacturing scale-up. The company's newsroom at IBN will provide ongoing updates on regulatory and commercial progress.
Forward-looking statements in the announcement, available with full disclaimers on the InvestorBrandNetwork website, highlight risks and uncertainties typical of early-stage medical device companies. These include the outcome of FDA review, market acceptance, and competitive dynamics.
